Literature DB >> 21415358

Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes.

Jennifer A Emond1, Ruth E Patterson, Loki Natarajan, Gail A Laughlin, Ellen B Gold, John P Pierce.   

Abstract

BACKGROUND: We examined if the reduced risk of breast cancer events seen among women without baseline hot flash symptoms in the Women's Healthy Eating and Living (WHEL) dietary intervention trial was related to changes in sex hormone concentrations.
METHODS: Baseline and year one concentrations of total and bioavailable estradiol, and testosterone and sex hormone-binding globulin (SHBG) were compared by intervention arm among 447 postmenopausal women without hot flashes. Cox proportional hazard models tested interaction terms between study arm and baseline hormone concentrations adjusted for study site, antiestrogen use, positive nodes, tumor size, oophorectomy status, and hormone replacement therapy use.
RESULTS: Sex hormone concentrations did not differ by study arm at baseline nor at year one. Twenty-two (9.8%) events occurred in the intervention arm versus 42 (18.9%) in the comparison arm (P = 0.009). Baseline bioavailable testosterone was significantly, positively associated with additional events (HR 1.69, 95% CI: 1.00-2.84; P = 0.049). There were significant interactions between the intervention and total (P = 0.015), and bioavailable (P = 0.050) testosterone: the intervention was more protective among participants with higher baseline total (HR 0.3, 95% CI: 0.2-0.7) or bioavailable (HR 0.4, 95% CI: 0.2-0.7) testosterone than for participants with lower baseline total (HR 0.8, 95% CI: 0.4-1.5) or bioavailable (HR 0.8, 95% CI: 0.4-1.5) testosterone. No significant effects were seen for estradiol or SHBG.
CONCLUSIONS: The WHEL dietary intervention may have modified other risk factors of recurrence correlated with testosterone. IMPACT: Sex hormones should be considered as part of a larger biological system related to the risk of breast cancer recurrence. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415358      PMCID: PMC3089679          DOI: 10.1158/1055-9965.EPI-10-1240

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  26 in total

1.  Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial.

Authors:  F Berrino; C Bellati; G Secreto; E Camerini; V Pala; S Panico; G Allegro; R Kaaks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-01       Impact factor: 4.254

2.  Reliability and interrelations among serum sex hormones in postmenopausal women.

Authors:  J A Cauley; J P Gutai; L H Kuller; J G Powell
Journal:  Am J Epidemiol       Date:  1991-01       Impact factor: 4.897

3.  Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial.

Authors:  Grace Mariko Kalish; Elizabeth Barrett-Connor; Gail A Laughlin; Barbara I Gulanski
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

4.  Fasting glucose is a risk factor for breast cancer: a prospective study.

Authors:  Paola Muti; Teresa Quattrin; Brydon J B Grant; Vittorio Krogh; Andrea Micheli; Holger J Schünemann; Malathi Ram; Jo L Freudenheim; Sabina Sieri; Maurizio Trevisan; Franco Berrino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-11       Impact factor: 4.254

5.  Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

Authors:  Pamela J Goodwin; Marguerite Ennis; Kathleen I Pritchard; Maureen E Trudeau; Jarley Koo; Yolanda Madarnas; Warren Hartwick; Barry Hoffman; Nicky Hood
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

6.  Effects of a high-fiber, low-fat diet intervention on serum concentrations of reproductive steroid hormones in women with a history of breast cancer.

Authors:  Cheryl L Rock; Shirley W Flatt; Cynthia A Thomson; Marcia L Stefanick; Vicky A Newman; Lovell A Jones; Loki Natarajan; Cheryl Ritenbaugh; Kathryn A Hollenbach; John P Pierce; R Jeffrey Chang
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

Review 7.  Pathophysiology and treatment of hot flashes.

Authors:  Tait D Shanafelt; Debra L Barton; Alex A Adjei; Charles L Loprinzi
Journal:  Mayo Clin Proc       Date:  2002-11       Impact factor: 7.616

8.  Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease.

Authors:  Shrita M Patel; Sarah J Ratcliffe; Muredach P Reilly; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; Kim Sutton-Tyrrell; John Robbins; Linda P Fried; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2009-10-21       Impact factor: 5.958

9.  Estrogen levels in postmenopausal women with hot flashes.

Authors:  Y Erlik; D R Meldrum; H L Judd
Journal:  Obstet Gynecol       Date:  1982-04       Impact factor: 7.661

10.  Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature.

Authors:  R Södergård; T Bäckström; V Shanbhag; H Carstensen
Journal:  J Steroid Biochem       Date:  1982-06       Impact factor: 4.292

View more
  7 in total

1.  Endogenous estradiol is not associated with poor physical health in postmenopausal breast cancer survivors.

Authors:  H Irene Su; Laura Y Sue; Shirley W Flatt; Loki Natarajan; Ruth E Patterson; John P Pierce
Journal:  J Womens Health (Larchmt)       Date:  2013-10-10       Impact factor: 2.681

2.  Postdiagnosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project.

Authors:  Marilyn L Kwan; Wendy Y Chen; Shirley W Flatt; Erin K Weltzien; Sarah J Nechuta; Elizabeth M Poole; Michelle D Holmes; Ruth E Patterson; Xiao Ou Shu; John P Pierce; Bette J Caan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-11-13       Impact factor: 4.254

Review 3.  Impact of Diet, Body Mass Index, and Physical Activity on Cancer Survival.

Authors:  Ellen Kampman; Alina Vrieling; Fränzel J van Duijnhoven; Renate M Winkels
Journal:  Curr Nutr Rep       Date:  2012-01-07

4.  Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial.

Authors:  Michael J Hale; Anthony Howell; Mitch Dowsett; Jack Cuzick; Ivana Sestak
Journal:  Breast       Date:  2020-10-31       Impact factor: 4.380

5.  Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer Patients.

Authors:  Mark E Sherman; Laura Ichikawa; Ruth M Pfeiffer; Diana L Miglioretti; Karla Kerlikowske; Jeffery Tice; Pamela M Vacek; Gretchen L Gierach
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

6.  PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer.

Authors:  Huiyu Xu; Yong Han; Jiaying Lou; Hongxian Zhang; Yue Zhao; Balázs Győrffy; Rong Li
Journal:  Oncotarget       Date:  2017-05-13

7.  Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.

Authors:  Elisabetta Venturelli; Annalisa Orenti; Aline S C Fabricio; Giulia Garrone; Roberto Agresti; Biagio Paolini; Chiara Bonini; Massimo Gion; Franco Berrino; Christine Desmedt; Danila Coradini; Elia Biganzoli
Journal:  BMC Cancer       Date:  2018-06-13       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.